fig3

Figure 3. Effect of CPT on disease phenotypes in FAD iPSC derived neurons. (A) Immunostainings and data quantification showing the effect of CPT treatment on mOC78 positive beta-amyloid aggregates in control iPSC neurons and FAD iPSC neurons treated with vehicle or CPT; (B) Immunostainings and data quantification showing the effect of CPT treatment on CP13 positive p-tau signals in control iPSC neurons and FAD iPSC neurons treated with vehicle or CPT; (C) Immunostainings and data quantification showing the effect of CPT treatment on total tau signals in control iPSC neurons and FAD iPSC neurons treated with vehicle or CPT; (D) Immunostainings and data quantification showing the effect of CPT treatment on Rab5 positive early endosome signals in control iPSC neurons and FAD iPSC neurons treated with vehicle or CPT. ***P < 0.001, ns: not significant, in Student’s t-test or one-way ANOVA test. CPT: CPT2008, 6-chloro-3-(2,4-dichloro-5-methoxyphenyl)-2-mecapto-7-methoxyquinazolin-4(3H)-one; FAD: familial Alzheimer’s disease; iPSC: induced pluripotent stem cell.